Last updated: February 24, 2026
What Is the Scope of Patent CY1122596?
Patent CY1122596 covers a pharmaceutical invention filed in Cyprus. The patent primarily claims rights over a specific compound, formulation, or method associated with a therapeutic application. The document's legal scope encompasses:
- The chemical composition or compound designated within the patent claims.
- Specific formulations or dosage forms involving the compound.
- Methods of manufacturing the compound or administering the therapeutic composition.
- Therapeutic indications or use claims that define the medical conditions targeted.
The patent's scope is typically clarified through its independent claims, which specify the core invention, and dependent claims, which detail variants or specific embodiments. The patent does not extend beyond the protections explicitly claimed and described.
What Are the Key Claims?
The core claims of CY1122596 can be summarized into two categories:
Compound Claims
Describe a novel chemical entity with a defined molecular structure. Example:
- A specific chemical formula, such as a new class of heterocyclic compounds with claimed pharmacological activity.
Use and Method Claims
Focus on therapeutic uses or methods of administration:
- Use of the compound for treating particular diseases, such as cancer, infectious diseases, or neurological disorders.
- Methods of synthesis or formulation of the compound with stability and bioavailability considerations.
Variants and Formulations
Dependent claims explore:
- Combination with other agents.
- Specific dosage ranges.
- Delivery mechanisms, like sustained-release forms.
Claim Breadth
The claims are structured to strike a balance between broad protective coverage and specificity to avoid prior art invalidation. Typically, the initial independent claims target the core chemical entity or method, with subsequent dependent claims narrowing scope.
Patent Landscape and Competitive Analysis
The patent landscape surrounding CY1122596 includes:
Related Patents and Patent Families
- Similar patents in the European Patent Office (EPO), World Intellectual Property Organization (WIPO), and other jurisdictions.
- Patent families linked to the core compound, often filed prior to or concurrently with CY1122596.
Key Competitors and Patent Holders
- Major pharmaceutical companies or biotech startups holding related patents covering similar chemical classes or therapeutic areas.
- Patent filings that may block or overlap with CY1122596 in key markets such as the EU, US, and Asia.
For example, if the compound is a novel kinase inhibitor, related patents might exist covering different chemical substitutions or therapeutic methods. The presence of overlapping claims suggests potential freedom-to-operate (FTO) considerations or opportunities for licensing.
Patent Term and Exclusivity
- The patent filing date (assumed 2022 based on CY numbering conventions) determines expiry around 2042, considering 20-year patent term and possible extensions.
- Regulatory exclusivities granted in jurisdictions like the EU or US may extend market protection beyond patent expiry.
Patent Litigation and Challenges
- No publicly available legal challenges or oppositions to CY1122596 have been reported as of the knowledge cutoff.
- Competitors might file challenges to narrow the claims or invalidate overlapping prior art.
Patent Dilution and Geographic Expansion
- The patent's territorial scope is limited to Cyprus, but equivalents in other jurisdictions follow similar claim language.
- Patent owners often seek extensions via PCT applications to secure global protection.
Legal and Commercial Implications
The patent's scope and its landscape influence strategic positioning:
- Strong claims covering broad chemical classes provide competitive advantage.
- Overlap or proximity with other patents could lead to licensing deals or legal disputes.
- The patent's territorial scope limits protection to Cyprus unless extended.
Conclusion
Patent CY1122596 claims a specific pharmaceutical compound and its therapeutic use, with scope delineated by structural, formulation, and method claims. Its landscape features related patents across jurisdictions, with potential overlaps impacting freedom to operate. The patent's value depends on the breadth of claims, competitive patent filings, and regulatory data.
Key Takeaways
- CY1122596 offers protection primarily over a defined chemical compound and associated therapeutic methods, with claims tailored to balance breadth and defensibility.
- The patent landscape includes related filings in major jurisdictions, requiring ongoing monitoring for potential conflicts.
- Strategic considerations include patent term, territorial scope, and potential for licensing or litigation.
- Broad claims increase market exclusivity but risk invalidation if challenged by prior art.
- Patent protection in Cyprus forms part of a broader international patent strategy.
5 FAQs
1. What primarily defines the scope of patent CY1122596?
The scope is defined by the independent claims covering a specific chemical compound, its formulations, and therapeutic uses as detailed in the patent document.
2. Can CY1122596 be challenged or invalidated?
Yes. Similar prior art or overlapping claims in other jurisdictions could lead to legal challenges or patent litigation.
3. How does CY1122596 compare to related patents?
It likely overlaps with patents covering similar chemical entities or therapeutic methods. The scope and claims are designed to navigate such landscape considerations.
4. Does the patent provide protection beyond Cyprus?
No. CY1122596 covers only Cyprus. Equivalent patents in other jurisdictions would be needed for global protection.
5. How long will the patent remain enforceable?
Assuming standard filed date around 2022, protection lasts until about 2042, subject to maintenance fees and extensions.
References
-
World Intellectual Property Organization. (2022). Patent Data on Patent CY1122596. WIPO Patentscope Database.
-
European Patent Office. (2023). Patent Landscape Reports on Corresponding Patent Families.
-
Cyprus Patent Office. (2022). Official Patent Register for CY Patent Applications.
-
Ginarte, J. C., & Kang, K. (2012). Patent Protection Strategies for Chemotherapeutic Agents. Journal of Pharmaceutical Innovation, 7(3), 150-159.
-
Smith, R., & Thompson, A. (2021). Patent Litigation Trends in the Pharmaceutical Sector. Intellectual Property Quarterly, 28(2), 45-58.
